Piper Sandler maintains Replimune Group at Overweight, raises price target to $27 from $14
Piper Sandler kept its Overweight rating on Replimune Group and raised its price target to $27 from $14, suggesting a 23.3% upside from the Nov 13 close of $21.89.
How this was made

The 30-second read
Why it matters
The price target hike could attract new buyers and support the stock price.
Market read
Analyst upgrade may provide a short-term catalyst for RPLM.
What to watch
Potential regulatory or clinical trial setbacks could temper upside.
Background
Piper Sandler's analyst report updates the valuation of Replimune Group.
Market effects
May lift sentiment in the biotech/oncology sector.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
Target may be overly optimistic given limited data on product pipeline.
Key entities
- companyReplimune Group
Biotech firm focused on oncolytic virus therapies.
- analystPiper Sandler
Investment bank providing the rating upgrade.

